Therapeutic options of Angiotensin Receptor Neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition

详细信息    查看全文

• 作者：Maurizio Volterrani^a ; ^{maurizio.volterrani@sanraffaele.it} ; Ferdinando Iellamo^a ; ^b ; Michele Senni^c ; Massimo F. Piepoli^d ; ¹
• 关键词：Chronic heart failure ; Renin&ndash ; angiotensin&ndash ; aldosterone system ; Natriuretic peptide system ; Natriuretic peptide inhibitors ; Cardiac outcomes
• 刊名：International Journal of Cardiology
• 出版年：2017
• 出版时间：1 January 2017
• 年：2017
• 卷：226
• 期：Complete
• 页码：132-135
• 全文大小：234 K
• 卷排序：226

文摘

In heart failure, in addition to the renin–angiotensin–aldosterone system and sympathetic nervous system, the natriuretic peptide (NP) system plays a fundamental role among compensating mechanisms. The NPs undergo rapid enzymatic degradation that limits their vasorelaxant, natriuretic, and diuretic actions. Degradation of NPs is partially due to the action of neprilysin, which is a membrane-bound endopeptidase found in many tissues. This article summarizes recent findings on a new natriuretic peptide-enhancing drug and their implication for future pharmacological treatment of patients suffering from heart failure with reduced ejection fraction.